Rhythm Biosciences announces Dr David Atkins as new CEO

Rhythm Biosciences Ltd (ASX: $RHY) has appointed Dr David Atkins as its new Chief Executive Officer (CEO), effective from Monday, 13 May 2024. Dr Atkins, an accomplished global healthcare leader with extensive experience in R&D, product development, and commercialization across various life sciences and healthcare disciplines, was selected following a comprehensive search process led by the Board with assistance from executive search firm Proclinical Executive and executive diagnostic consultants, Aspect Group.

Dr David Atkins on his appointment as CEO

Dr David Atkins expressed his delight about the opportunity to become CEO of Rhythm, emphasizing the potential role of the company's product set in detecting various cancers early, globally. He also highlighted the strong growth potential in delivering a robust platform of research, initially developed by CSIRO, and expressed eagerness to work with the RHY team and broader stakeholders to accelerate RHY's positive impact on cancer patients.

Rhythm Biosciences' future under Dr David Atkins' leadership

The appointment of Dr David Atkins as CEO marks a significant milestone for Rhythm Biosciences, bringing in a leader with a wealth of global healthcare experience. With Dr Atkins at the helm, the company aims to advance its current product pipeline and explore ways to accelerate its impact on cancer patients, both in Australia and globally. The company's commitment to delivering simple, affordable blood tests for accurate and early detection of cancers, particularly colorectal cancer, remains at the forefront of its corporate strategy. Dr Atkins' extensive experience and strategic vision are expected to steer Rhythm Biosciences towards achieving its ambitions and goals in the field of predictive cancer diagnostics technology.